3-氧-3-(4-嘧啶基)甲基丙酸酯 | 75399-06-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-氧-3-(4-嘧啶基)甲基丙酸酯
• 英文名称: Methyl 3-oxo-3-(pyrimidin-4-yl)propanoate
• 英文别名: methyl 3-oxo-3-pyrimidin-4-ylpropanoate
• CAS: 75399-06-3
• 化学式: C₈H₈N₂O₃
• 分子量: 180.163
• InChiKey: IXVCHLNEYOOGLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  69.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  乙酸甲酯 、 嘧啶-4-甲酸甲酯 在 sodium hydride 作用下， 以 乙二醇二甲醚 为溶剂， 以23%的产率得到3-氧-3-(4-嘧啶基)甲基丙酸酯
  参考文献：
  名称：

  Strengthening and toughening of cordierite by the addition of silicon carbide whiskers, platelets and particles

  摘要：

  DOI：

  10.1007/bf00553708

文献信息

• Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives
  申请人：——

  公开号：US20030225274A1

  公开（公告）日：2003-12-04

  The present invention relates to a process for preparing stereoisomerically enriched 3-heteroaryl-3-hydroxycarboxylic esters by reducing 3-heteroaryl-3-oxocarboxylic esters in the presence of ruthenium-containing catalysts.

  本发明涉及一种在含有钌催化剂的情况下还原3-杂环基-3-酮羧酸酯以制备立体异构富集的3-杂环基-3-羟基羧酸酯的方法。
• [EN] SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES<br/>[FR] DERIVES DE 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-A]PYRIMIDIN-6-ONE SUBSTITUES
  申请人：SANOFI AVENTIS

  公开号：WO2005058908A1

  公开（公告）日：2005-06-30

  The invention relates to a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof: (I) wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a carbonyl group, a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted; R2 represents a benzene ring or a naphthalene ring; the rings being optionally substituted; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl carbonyl group, a benzoyl group, a C1-6 alkyl group, the groups being optionally substituted; o and m represent 1 to 2; n represents 0 to 3; p represents 0 to 2; and q represents 0 to 2. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种由式(I)表示的二氢螺-[环烷基胺]-嘧啶酮衍生物或其盐：（I）其中：X代表两个氢原子、硫原子、氧原子或C1-2烷基和氢原子；Y代表键、羰基基团、可选取代的亚甲基基团；R1代表2、3或4-吡啶环或2、4或5-嘧啶环，环上可选取代；R2代表苯环或萘环，环上可选取代；R3代表氢原子、C1-6烷基或卤素原子；R4代表氢原子、C1-4烷氧羰基基团、C3-6环烷基羰基基团、苯甲酰基基团、C1-6烷基，基团上可选取代；o和m代表1到2；n代表0到3；p代表0到2；q代表0到2。本发明还涉及一种药物制剂，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES
  申请人：CHEREZE Nathalie

  公开号：US20070010539A1

  公开（公告）日：2007-01-11

  The invention relates to a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, o, m, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种由式(I)表示的二氢螺-[环烷基胺]-嘧啶酮衍生物或其盐：其中X、Y、R1、R2、R3、R4、o、m、n、p和q如本文所定义。本发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• Verfahren zur Reduktion von 3-Heteroaryl-3-Oxopropionsäurederivaten
  申请人：BAYER AG

  公开号：EP1340746A1

  公开（公告）日：2003-09-03

  Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung stereoisomerenangereicherter 3-Heteroaryl-3-hydroxycarbonsäureester durch Reduktion von 3-Heteroaryl-3-oxocarbonsäureestern in Gegenwart von Ruthenium enthaltenden Katalysatoren.

  本发明涉及一种在含钌催化剂存在下通过还原 3-heteroaryl-3-oxocarboxylic acid esters 制备立体异构体丰富的 3-heteroaryl-3-hydroxycarboxylic acid esters 的工艺。
• Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2a] pyrimidin-6-one derivatives
  申请人：Sanofi-Aventis

  公开号：EP1557417A1

  公开（公告）日：2005-07-27

  The invention relates to a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a carbonyl group, a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted; R2 represents a benzene ring or a naphthalene ring; the rings being optionally substituted; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C1-6 alkyl group optionally substituted; o and m represent 1 to 2; n represents 0 to 3; p represents 0 to 2; and q represents 0 to 2. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种由式 (I) 或其盐代表的二氢螺-[环烷基胺]-嘧啶酮衍生物： 其中 X 代表两个氢原子、一个硫原子、一个氧原子或一个 C1-2 烷基和一个氢原子； Y 代表键、羰基、任选取代的亚甲基； R1 代表 2、3 或 4-吡啶环或 2、4 或 5-嘧啶环，环可任选被取代； R2 代表苯环或萘环；这些环可任选被取代； R3 代表氢原子、C1-6 烷基或卤素原子； R4 代表氢原子、C1-4 烷氧基羰基、任选被取代的 C1-6 烷基； o 和 m 代表 1 至 2 n 代表 0 至 3 p 代表 0 至 2；以及 q 代表 0 至 2。 本发明还涉及一种包含上述衍生物或其盐作为活性成分的药物，该药物用于预防和/或治疗由 GSK3β 活性异常引起的神经退行性疾病，如阿尔茨海默病。